HER2 testing in the UK: further update to recommendations
- PMID: 18381380
- DOI: 10.1136/jcp.2007.054866
HER2 testing in the UK: further update to recommendations
Abstract
These guidelines update the previous UK HER2 testing guidelines and have been formulated to give advice on methodology, interpretation and quality assurance to ensure that HER2 testing results are accurate, reliable and timely with the expansion of testing to all patients with breast cancer at the time of primary diagnosis. The recommendations for testing are the use of immunohistochemistry but with analysis of equivocal cases by in situ hybridisation to clarify their HER2 status or the use of frontline fluorescence in situ hybridisation (FISH) testing for those laboratories wishing to do so; the inclusion of a chromosome 17 probe is strongly recommended. Laboratories using chromogenic or silver in situ hybridisation should perform an initial validation against FISH. For immunohistochemistry and in situ hybridisation there must be participation in the appropriate National External Quality Assurance scheme.
Similar articles
-
HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods.J Clin Pathol. 2011 Aug;64(8):649-53. doi: 10.1136/jcp.2011.089847. Epub 2011 Jun 20. J Clin Pathol. 2011. PMID: 21690244
-
Updated UK Recommendations for HER2 assessment in breast cancer.J Clin Pathol. 2015 Feb;68(2):93-9. doi: 10.1136/jclinpath-2014-202571. Epub 2014 Dec 8. J Clin Pathol. 2015. PMID: 25488926 Free PMC article.
-
Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.Hum Pathol. 2013 Nov;44(11):2590-6. doi: 10.1016/j.humpath.2013.07.005. Epub 2013 Sep 25. Hum Pathol. 2013. PMID: 24075600
-
HER2 testing in breast cancer: NCCN Task Force report and recommendations.J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. J Natl Compr Canc Netw. 2006. PMID: 16813731 Review.
-
[Assessment of HER2 status in breast cancer].Bull Cancer. 2004 Dec 1;91 Suppl 4:S211-5. Bull Cancer. 2004. PMID: 15899610 Review. French.
Cited by
-
A radiologist's guide to novel anticancer therapies in the era of precision medicine.Eur J Radiol Open. 2022 Mar 2;9:100406. doi: 10.1016/j.ejro.2022.100406. eCollection 2022. Eur J Radiol Open. 2022. PMID: 35265736 Free PMC article. Review.
-
Clinical Potential of miR-451 and miR-506 as a Prognostic Biomarker in Patients with Breast Cancer.J Healthc Eng. 2022 Jan 11;2022:9578788. doi: 10.1155/2022/9578788. eCollection 2022. J Healthc Eng. 2022. Retraction in: J Healthc Eng. 2023 Aug 16;2023:9870383. doi: 10.1155/2023/9870383. PMID: 35070246 Free PMC article. Retracted.
-
Updates on breast biomarkers.Virchows Arch. 2022 Jan;480(1):163-176. doi: 10.1007/s00428-022-03267-x. Epub 2022 Jan 14. Virchows Arch. 2022. PMID: 35029776 Review.
-
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.Cancer Discov. 2021 Oct;11(10):2474-2487. doi: 10.1158/2159-8290.CD-20-1557. Epub 2021 May 3. Cancer Discov. 2021. PMID: 33941592 Free PMC article. Clinical Trial.
-
A novel approach for microRNA in situ hybridization using locked nucleic acid probes.Sci Rep. 2021 Feb 24;11(1):4504. doi: 10.1038/s41598-021-83888-5. Sci Rep. 2021. PMID: 33627751 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous